GARFIELD-AF is the largest global prospective atrial fibrillation (AF) registry. The aim of the registry is to determine the real world clinical management and outcomes of patients newly diagnosed patients with non-valvular AF with at least one additional risk factor for stroke.

The UK component of GARFIELD-AF was primary care based. 3,580 patients newly diagnosed with AF were enrolled in five sequential cohorts from June 2011 - August 2016 and followed up for a minimum of two years. The study ended in 2019 and publications are ongoing. More information can be found on the GARFIELD-AF Registry website.

Funded by	GARFIELD-AF is sponsored by Thrombosis Research Institute and funded through an educational research grant from Bayer Pharma AG.
Research team members	David Fitzmaurice, Patricia Apenteng
Collaborators	Thrombosis Research Institute
Dates	March 2011 to February 2020

Enquiries:

Dr Patricia Apenteng

p.apenteng@warwick.ac.uk

Publications:

Apenteng, P.N., Murray, E.T., Holder, R. et al.An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol

BMC Cardiovasc Disord 13, 31 (2013). https://doi.org/10.1186/1471-2261-13-31